Clinical Cancer Research Versailles No Abst Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Argani, P.
Right arrow Articles by Hruban, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Argani, P.
Right arrow Articles by Hruban, R. H.
Clinical Cancer Research Vol. 7, 3862-3868, December 2001
© 2001 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas

Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE)1

Pedram Argani2, Christine Iacobuzio-Donahue, Byungwoo Ryu, Christophe Rosty, Michael Goggins, Robb E. Wilentz, Selva R. Murugesan, Steven D. Leach, Elizabeth Jaffee, Charles J. Yeo, John L. Cameron, Scott E. Kern and Ralph H. Hruban

Departments of Pathology [P. A., C. I-D., C. R., M. G., R. E. W., S. R. M., E. J., S. E. K., R. H. H.], Oncology [B. R., S. D. L., E. J., C. J. Y., S. E. K., R. H. H.], Medicine [M. G.], and Surgery [S. D. L., C. J. Y., J. L. C.], The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231-2410

Purpose: Effective new markers of pancreatic carcinoma are urgently needed. In a previous analysis of gene expression in pancreatic adenocarcinoma using serial analysis of gene expression (SAGE), we found that the tag for the mesothelin mRNA transcript was present in seven of eight SAGE libraries derived from pancreatic carcinomas but not in the two SAGE libraries derived from normal pancreatic duct epithelial cells. In this study, we evaluate the potential utility of mesothelin as a tumor marker for pancreatic adenocarcinoma.

Experimental Design: Mesothelin mRNA expression was evaluated in pancreatic adenocarcinomas using reverse-transcription PCR (RT-PCR) and in situ hybridization, whereas mesothelin protein expression was evaluated by immunohistochemistry.

Results: Using an online SAGE database (http://www.ncbi.nlm.gov/SAGE), we found the tag for mesothelin to be consistently present in the mesothelioma, ovarian cancer, and pancreatic cancer libraries but not in normal pancreas libraries. Mesothelin mRNA expression was confirmed by in situ hybridization in 4 of 4 resected primary pancreatic adenocarcinomas and by RT-PCR in 18 of 20 pancreatic cancer cell lines, whereas mesothelin protein expression was confirmed by immunohistochemistry in all 60 resected primary pancreatic adenocarcinomas studied. The adjacent normal pancreas in these 60 cases did not label, or at most only rare benign pancreatic ducts showed weak labeling for mesothelin.

Conclusions: Mesothelin is a new marker for pancreatic adenocarcinoma identified by gene expression analysis. Mesothelin overexpression in pancreatic adenocarcinoma has potential diagnostic, imaging, and therapeutic implications.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Y. Feng, X. Xiao, Z. Zhu, E. Streaker, M. Ho, I. Pastan, and D. S. Dimitrov
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
Mol. Cancer Ther., May 1, 2009; 8(5): 1113 - 1118.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Carpenito, M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, et al.
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
PNAS, March 3, 2009; 106(9): 3360 - 3365.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
U. Bharadwaj, M. Li, C. Chen, and Q. Yao
Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3
Mol. Cancer Res., November 1, 2008; 6(11): 1755 - 1765.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. A. Danovi, H. H. Wong, and N. R. Lemoine
Targeted therapies for pancreatic cancer
Br. Med. Bull., September 1, 2008; 87(1): 97 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tsuruta, L. Pereboeva, M. Breidenbach, D. T. Rein, M. Wang, R. D. Alvarez, G. P. Siegal, P. Dent, P. B. Fisher, and D. T. Curiel
A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3582 - 3588.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Alvarez, A. Corvalan, J. C. Roa, P. Argani, F. Murillo, J. Edwards, R. Beaty, G. Feldmann, S.-M. Hong, M. Mullendore, et al.
Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2631 - 2638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, et al.
Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases
Clin. Cancer Res., April 1, 2008; 14(7): 1938 - 1946.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
G. Feldmann and A. Maitra
Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts
J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Li, U. Bharadwaj, R. Zhang, S. Zhang, H. Mu, W. E. Fisher, F. C. Brunicardi, C. Chen, and Q. Yao
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
Mol. Cancer Ther., February 1, 2008; 7(2): 286 - 296.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, V. C. Broaddus, S. Wilson, D. J. Liewehr, and J. Zhang
Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts
Clin. Cancer Res., December 1, 2007; 13(23): 7166 - 7171.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Hucl, J. R. Brody, E. Gallmeier, C. A. Iacobuzio-Donahue, I. K. Farrance, and S. E. Kern
High Cancer-Specific Expression of Mesothelin (MSLN) Is Attributable to an Upstream Enhancer Containing a Transcription Enhancer Factor Dependent MCAT Motif
Cancer Res., October 1, 2007; 67(19): 9055 - 9065.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, S. Bullock, A. Premkumar, R. J. Kreitman, H. Kindler, M. C. Willingham, and I. Pastan
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
Clin. Cancer Res., September 1, 2007; 13(17): 5144 - 5149.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, J. Williams-Gould, S. M. Steinberg, D. J. Liewehr, J. Yokokawa, K. Y. Tsang, R. J. Surawski, T. Scott, and K. Camphausen
Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts.
Clin. Cancer Res., August 15, 2006; 12(16): 4983 - 4988.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Onda, S. Nagata, M. Ho, T. K. Bera, R. Hassan, R. H. Alexander, and I. Pastan
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Clin. Cancer Res., July 15, 2006; 12(14): 4225 - 4231.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno and M. Hidalgo
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Li, T. Sai, M. Berger, Q. Chao, D. Davidson, G. Deshmukh, B. Drozdowski, W. Ebel, S. Harley, M. Henry, et al.
Human antibodies for immunotherapy development generated via a human B cell hybridoma technology
PNAS, March 7, 2006; 103(10): 3557 - 3562.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Yen, C.-Y. Hsu, T.-L. Mao, T-C. Wu, R. Roden, T.-L. Wang, and I.-M. Shih
Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma
Clin. Cancer Res., February 1, 2006; 12(3): 827 - 831.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, A. T. Remaley, M. L. Sampson, J. Zhang, D. D. Cox, J. Pingpank, R. Alexander, M. Willingham, I. Pastan, and M. Onda
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 447 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
M. Gronborg, T. Z. Kristiansen, A. Iwahori, R. Chang, R. Reddy, N. Sato, H. Molina, O. N. Jensen, R. H. Hruban, M. G. Goggins, et al.
Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach
Mol. Cell. Proteomics, January 1, 2006; 5(1): 157 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Yokokawa, C. Palena, P. Arlen, R. Hassan, M. Ho, I. Pastan, J. Schlom, and K. Y. Tsang
Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin
Clin. Cancer Res., September 1, 2005; 11(17): 6342 - 6351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Onda, M. Willingham, S. Nagata, T. K. Bera, R. Beers, M. Ho, R. Hassan, R. J. Kreitman, and I. Pastan
New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA
Clin. Cancer Res., August 15, 2005; 11(16): 5840 - 5846.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
R. Chen, S. Pan, T. A. Brentnall, and R. Aebersold
Proteomic Profiling of Pancreatic Cancer for Biomarker Discovery
Mol. Cell. Proteomics, April 1, 2005; 4(4): 523 - 533.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. T. Garnett, C. Palena, M. Chakarborty, K.-Y. Tsang, J. Schlom, and J. W. Hodge
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes
Cancer Res., November 1, 2004; 64(21): 7985 - 7994.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, T. Bera, and I. Pastan
Mesothelin: A New Target for Immunotherapy
Clin. Cancer Res., June 15, 2004; 10(12): 3937 - 3942.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Koopmann, P. Buckhaults, D. A. Brown, M. L. Zahurak, N. Sato, N. Fukushima, L. J. Sokoll, D. W. Chan, C. J. Yeo, R. H. Hruban, et al.
Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers
Clin. Cancer Res., April 1, 2004; 10(7): 2386 - 2392.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Rump, Y. Morikawa, M. Tanaka, S. Minami, N. Umesaki, M. Takeuchi, and A. Miyajima
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
J. Biol. Chem., March 5, 2004; 279(10): 9190 - 9198.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. Sato, N. Fukushima, A. Maitra, C. A. Iacobuzio-Donahue, N. T. van Heek, J. L. Cameron, C. J. Yeo, R. H. Hruban, and M. Goggins
Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas
Am. J. Pathol., March 1, 2004; 164(3): 903 - 914.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. A. Iacobuzio-Donahue, R. Ashfaq, A. Maitra, N. V. Adsay, G. L. Shen-Ong, K. Berg, M. A. Hollingsworth, J. L. Cameron, C. J. Yeo, S. E. Kern, et al.
Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies
Cancer Res., December 15, 2003; 63(24): 8614 - 8622.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Maitra, D. E. Hansel, P. Argani, R. Ashfaq, A. Rahman, A. Naji, S. Deng, J. Geradts, L. Hawthorne, M. G. House, et al.
Global Expression Analysis of Well-Differentiated Pancreatic Endocrine Neoplasms Using Oligonucleotide Microarrays
Clin. Cancer Res., December 1, 2003; 9(16): 5988 - 5995.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Sato, A. Maitra, N. Fukushima, N. T. van Heek, H. Matsubayashi, C. A. Iacobuzio-Donahue, C. Rosty, and M. Goggins
Frequent Hypomethylation of Multiple Genes Overexpressed in Pancreatic Ductal Adenocarcinoma
Cancer Res., July 15, 2003; 63(14): 4158 - 4166.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. D. Logsdon, D. M. Simeone, C. Binkley, T. Arumugam, J. K. Greenson, T. J. Giordano, D. E. Misek, and S. Hanash
Molecular Profiling of Pancreatic Adenocarcinoma and Chronic Pancreatitis Identifies Multiple Genes Differentially Regulated in Pancreatic Cancer
Cancer Res., May 15, 2003; 63(10): 2649 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. A. Iacobuzio-Donahue, A. Maitra, M. Olsen, A. W. Lowe, N. T. Van Heek, C. Rosty, K. Walter, N. Sato, A. Parker, R. Ashfaq, et al.
Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays
Am. J. Pathol., April 1, 2003; 162(4): 1151 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. A. Iacobuzio-Donahue, A. Maitra, G. L. Shen-Ong, T. van Heek, R. Ashfaq, R. Meyer, K. Walter, K. Berg, M. A. Hollingsworth, J. L. Cameron, et al.
Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology
Am. J. Pathol., April 1, 2002; 160(4): 1239 - 1249.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.